karlak's Cancer Blog

May 13, 2009

I thought this was good information.
Those of us that have already had a treatment, this if still good information.
For those that are looking for answers this is important information.

Newswise — Researchers at The Cancer Institute of New Jersey (CINJ) have launched a clinical trial that targets a new treatment combination for the most common type of non-invasive breast cancer known as ductal carcinoma in situ (DCIS). CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

In DCIS, the cancer cells are inside the milk ducts of the breast but have not spread to surrounding breast tissue. According to the American Cancer Society, one in five new breast cancer cases in the United States is diagnosed as DCIS, and nearly all diagnosed at this early stage can be cured.

The trial, sponsored by the National Surgical Adjuvant Breast and Bowel Project (NSABP), will compare the effects of adding the drug trastuzumab to radiation therapy following breast sparing surgery (lumpectomy) in patients whose DCIS makes too much of the protein known as HER2 (positive). Too much of this protein can cause a normal cell to turn cancerous and make existing cancer cells grow faster. Trastuzumab is considered a targeted therapy against HER2-positive breast cancer. Early information shows the drug may also help radiation therapy work better in treating HER2-positive breast cancer, although investigators caution more research is needed in this area.

Trastuzumab has approval from the U.S. Food and Drug Administration (FDA) for the treatment of HER2-positive breast cancer together with chemotherapy, but it is considered “investigational” in this trial, because its use in combination with radiation therapy has not been FDA approved. The primary aim of this study is to see if this new combination is more effective in preventing occurrence of DCIS in the same breast or in other parts of the body, versus giving radiation by itself following lumpectomy.

Antoinette R. Tan, MD, a medical oncologist at CINJ and assistant professor of medicine at UMDNJ-Robert Wood Johnson Medical School, is the lead investigator of the study at CINJ. “A previous study by the NSABP shows an overall recurrence rate of eight percent in this population 12 years following breast conserving surgery and radiation. If we can add another element to the standard treatment, we could possibly reduce that rate even further,” she said. The study is seeking 2,000 participants at multiple cancer centers across the country.

Before taking part in the trial, interested participants will undergo a physical exam and a mammogram. Of those selected, one group will receive radiation therapy for three to six weeks as part of their regular treatment following surgery, while the other group will receive both radiation treatment and trastuzumab, which will be given through injection. Following treatment, participants will have follow-up physical exams and a mammogram each year for the next ten years.

Women over age 18 who have been diagnosed with HER2-positive DCIS and have had a lumpectomy are eligible to participate, although other criteria also must be met. For more information on how to take part, individuals should call CINJ’s Office of Human Research Services at 732-235-8675.